Assessing the impact of Trump’s first 100 days on science and health policy

Plus the return of biotech M&A, strong drug launches, and Eli Lilly's PBM problem.

May 2, 2025 Check out STAT+

Sponsored By

On this week's episode of the Readout LOUD, we review President Trump's first 100 days, the return of biotech M&A, and Eli Lilly's PBM problem.  Elaine, Allison and Adam gab about the week's relatively positive biotech news, including two acquisitions and a series of strong drug launches. What's a podcast without dipping into obesity, so Elaine will explain the latest maneuverings between Eli Lilly and Novo Nordisk around patient access and compounding. Then STAT editors Gideon Gil and Zach Tracer join to discuss their perspective overseeing STAT's reporting on science and politics during the first 100 days of the new administration. Listen Now Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes

---

---

Enjoying The Readout LOUD? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser